To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Additional recommended knowledge
In the 1940s, Ortho introduced the coil-spring diaphragm, and assisted in the development of the Papanicolaou smear stain to screen for cervical cancer.
In 1963, Ortho introduced the second oral contraceptive available in the United States (Ortho-Novum 10 and Ortho-Novum 2, produced by Syntex).
In 1973, Ortho and Syntex introduced the first progestogen only pills (mini-pills) available in the United States, Mirconor and Nor-QD.
In 1982, Ortho introduced the first biphasic oral contraceptive available in the United States, Ortho-Novum 10/11.
In 1992, Ortho introduced Ortho Tri-Cyclen in the United States, which in 1996 became the first oral contraceptive with an FDA-approved non-contraceptive indication (treatment of moderate acne).
In 1993, Ortho Pharmaceutical merged with McNeil Pharmaceutical in 1993 to form Ortho-McNeil Pharmaceutical.
In Canada, Ortho Products began operations in Montreal in 1941. The company started with one product and three employees and it was one of the first companies in Canada to make oral contraceptives. Moving to Toronto in 1944, the company outgrew a number of rented facilities until its own facilities were constructed in 1955. Continued growth required a number of plant expansions. Ortho Pharmaceutical Canada merged with McNeil Pharmaceutical Canada in 1991, and merged with Janssen Pharmaceutica Canada in 1995 to form Janssen-Ortho.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ortho_Pharmaceutical". A list of authors is available in Wikipedia.|